1250 related articles for article (PubMed ID: 22583038)
1. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
2. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
6. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
[No Abstract] [Full Text] [Related]
7. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
9. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
13. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
[TBL] [Abstract][Full Text] [Related]
14. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Neunert CE
Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
17. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
